

The committee-reported amendments were withdrawn.

The amendment (No. 2715) in the nature of a substitute was agreed to, as follows:

(Purpose: In the nature of a substitute)

Strike all after the enacting clause and insert the following:

#### SECTION 1. SHORT TITLE.

This Act may be cited as the “United States Anti-Doping Agency Reauthorization Act of 2020”.

#### SEC. 2. FINDINGS.

Congress makes the following findings:

(1) The United States Anti-Doping Agency—

(A) is the independent national anti-doping organization of the United States; and

(B) manages the anti-doping program, results management processes, drug reference resources, and athlete education for all United States Olympic Committee-recognized national governing bodies and the athletes and events of such national governing bodies.

(2) The United States Anti-Doping Agency contributes to the advancement of clean sport through scientific research, anti-doping education, and outreach programs, and the mission of the United States Anti-Doping Agency is to preserve the integrity of competition and protect the rights of athletes.

(3) Participation in youth sports has the potential to equip young athletes with important skills and values necessary for success in life, and it is essential that the culture of youth sports emphasizes such skills and values.

(4) The TrueSport program of the United States Anti-Doping Agency partners with youth sport organizations across the United States to promote sportsmanship, character building, and healthy performance through the use of targeted educational materials designed to promote a positive youth sport experience.

(5) In modifying the authority of the United States Anti-Doping Agency to include the promotion of the positive values of youth sport, Congress sends a strong signal that the goals of youth sport should include instilling in young athletes the values of integrity, respect, teamwork, courage, and responsibility.

(6) Due to the unique leadership position of the United States in the global community, adequate funding of the anti-doping and clean sport programs of the United States Anti-Doping Agency is imperative to the preparation for the 2028 Summer Olympic Games, which will be held in Los Angeles, California.

(7) Increased appropriations for fiscal years 2021 through 2029 would enable the United States Anti-Doping Agency to directly affect the integrity and well-being of sport, both domestically and internationally.

#### SEC. 3. MODIFICATIONS OF AUTHORITY.

Section 701 of the Office of National Drug Control Policy Reauthorization Act of 2006 (21 U.S.C. 2001) is amended—

(1) in subsection (b)—

(A) by amending paragraph (1) to read as follows:

“(1)(A) serve as the independent anti-doping organization for the amateur athletic competitions recognized by the United States Olympic and Paralympic Committee;

“(B) be responsible for certifying in advance any testing conducted by international organizations under the World Anti-Doping Code for international amateur athletes and athletic competitions occurring within the jurisdiction of the United States; and

“(C) be recognized worldwide as the independent national anti-doping organization for the United States;”;

(B) in paragraph (4), by striking the period at the end and inserting “; and”; and

(C) by adding at the end the following:

“(5) promote a positive youth sport experience by using a portion of the funding of the United States Anti-Doping Agency to provide educational materials on sportsmanship, character building, and healthy performance for the athletes, parents, and coaches who participate in youth sports.”; and

(2) by adding at the end the following:

“(c) DUE PROCESS IN ARBITRATION PROCEEDINGS.—Any action taken by the United States Anti-Doping Agency to enforce a policy, procedure, or requirement of the United States Anti-Doping Agency against a person with respect to a violation of Federal law, including an investigation, a disciplinary action, a sanction, or any other administrative action, shall be carried out in a manner that provides due process protection to the person.”.

#### SEC. 4. AUTHORIZATION OF APPROPRIATIONS.

Section 703 of the Office of National Drug Control Policy Reauthorization Act of 2006 (21 U.S.C. 2003) is amended to read as follows:

##### “SEC. 703. AUTHORIZATION OF APPROPRIATIONS.

“There are authorized to be appropriated to the United States Anti-Doping Agency—

“(1) for fiscal year 2021, \$15,500,000;

“(2) for fiscal year 2022, \$16,200,000;

“(3) for fiscal year 2023, \$16,900,000;

“(4) for fiscal year 2024, \$17,700,000;

“(5) for fiscal year 2025, \$18,500,000;

“(6) for fiscal year 2026, \$19,800,000;

“(7) for fiscal year 2027, \$22,100,000;

“(8) for fiscal year 2028, \$24,900,000; and

“(9) for fiscal year 2029, \$23,700,000.”.

#### SEC. 5. INFORMATION SHARING.

Except as otherwise prohibited by law and except in cases in which the integrity of a criminal investigation would be affected, pursuant to the obligation of the United States under Article 7 of the United Nations Educational, Scientific, and Cultural Organization International Convention Against Doping in Sport done at Paris October 19, 2005, and ratified by the United States in 2008, the Attorney General, the Secretary of Homeland Security, and the Commissioner of Food and Drugs shall provide to the United States Anti-Doping Agency any relevant information relating to the prevention of the use of performance-enhancing drugs or the prohibition of performance-enhancing methods.

The bill (S. 3248), as amended, was ordered to be engrossed for a third reading, was read the third time, and passed.

#### COMBATING PANDEMIC SCAMS ACT OF 2020

Mr. BRAUN. Mr. President, I ask unanimous consent that the Committee on Commerce, Science, and Transportation be discharged from further consideration of H.R. 6435 and the Senate proceed to its immediate consideration.

The PRESIDING OFFICER. Without objection, it is so ordered.

The clerk will report the bill by title.

The senior assistant legislative clerk read as follows:

A bill (H.R. 6435) to direct the Federal Trade Commission to develop and disseminate information to the public about scams related to COVID-19, and for other purposes.

There being no objection, the committee was discharged, and the Senate proceeded to consider the bill.

Mr. BRAUN. I ask unanimous consent that the bill be considered read a third time and passed and the motion to reconsider be considered made and laid upon the table.

The PRESIDING OFFICER. Without objection, it is so ordered.

The bill (H.R. 6435) was ordered to a third reading, was read the third time, and passed.

#### SCHOOL-BASED ALLERGIES AND ASTHMA MANAGEMENT PROGRAM ACT

Mr. BRAUN. Mr. President, I ask unanimous consent that the Committee on Health, Education, Labor, and Pensions be discharged from further consideration of H.R. 2468 and the Senate proceed to its immediate consideration.

The PRESIDING OFFICER. The clerk will report the bill by title.

The senior assistant legislative clerk read as follows:

A bill (H.R. 2468) to amend the Public Health Service Act to increase the preference given, in awarding certain allergies and asthma-related grants, to States that require certain public schools to have allergies and asthma management programs, and for other purposes.

There being no objection, the committee was discharged, and the Senate proceeded to consider the bill.

Mr. BRAUN. I ask unanimous consent that the bill be considered read a third time.

The PRESIDING OFFICER. Without objection, it is so ordered.

The bill was ordered to a third reading and was read the third time.

Mr. BRAUN. I know of no further debate on the bill.

The PRESIDING OFFICER. If there is no further debate on the bill, the bill having been read the third time, the question is, Shall the bill pass?

The bill (H.R. 2468) was passed.

Mr. BRAUN. I ask unanimous consent that the motion to reconsider be considered made and laid upon the table.

The PRESIDING OFFICER. Without objection, it is so ordered.

#### ADVANCING EDUCATION ON BIOSIMILARS ACT OF 2019

Mr. BRAUN. Mr. President, I ask unanimous consent that the Committee on Health, Education, Labor, and Pensions be discharged from further consideration of S. 1681 and the Senate proceed to its immediate consideration.

The PRESIDING OFFICER. The clerk will report the bill by title.

The senior assistant legislative clerk read as follows:

A bill (S. 1681) to educate health care providers and the public on biosimilar biological products, and for other purposes.

There being no objection, the committee was discharged, and the Senate proceeded to consider the bill.

Mr. BRAUN. I ask unanimous consent that the Alexander substitute amendment at the desk be agreed to that the bill, as amended, be considered read a third time and passed; and that the motion to reconsider be considered made and laid upon the table.

The PRESIDING OFFICER. Without objection, it is so ordered.

The amendment (No. 2716) in the nature of a substitute was agreed to, as follows

(Purpose: In the nature of a substitute)

Strike all after the enacting clause and insert the following:

#### SECTION 1. SHORT TITLE.

This Act may be cited as the “Advancing Education on Biosimilars Act of 2020”.

#### SEC. 2. EDUCATION ON BIOLOGICAL PRODUCTS.

Subpart 1 of part F of title III of the Public Health Service Act (42 U.S.C. 262 et seq.) is amended by adding at the end the following:

##### “SEC. 352A. EDUCATION ON BIOLOGICAL PRODUCTS.

“(a) INTERNET WEBSITE.—

“(1) IN GENERAL.—The Secretary may maintain and operate an internet website to provide educational materials for health care providers, patients, and caregivers, regarding the meaning of the terms, and the standards for review and licensing of, biological products, including biosimilar biological products and interchangeable biosimilar biological products.

“(2) CONTENT.—Educational materials provided under paragraph (1) may include—

“(A) explanations of key statutory and regulatory terms, including ‘biosimilar’ and ‘interchangeable’, and clarification regarding the use of interchangeable biosimilar biological products;

“(B) information related to development programs for biological products, including biosimilar biological products and interchangeable biosimilar biological products and relevant clinical considerations for prescribers, which may include, as appropriate and applicable, information related to the comparability of such biological products;

“(C) an explanation of the process for reporting adverse events for biological products, including biosimilar biological products and interchangeable biosimilar biological products; and

“(D) an explanation of the relationship between biosimilar biological products and interchangeable biosimilar biological products licensed under section 351(k) and reference products (as defined in section 351(i)), including the standards for review and licensing of each such type of biological product.

“(3) FORMAT.—The educational materials provided under paragraph (1) may be—

“(A) in formats such as webinars, continuing education modules, videos, fact sheets, infographics, stakeholder toolkits, or other formats as appropriate and applicable; and

“(B) tailored for the unique needs of health care providers, patients, caregivers, and other audiences, as the Secretary determines appropriate.

“(4) OTHER INFORMATION.—In addition to the information described in paragraph (2), the Secretary shall continue to publish—

“(A) the action package of each biological product licensed under subsection (a) or (k) of section 351; or

“(B) the summary review of each biological product licensed under subsection (a) or (k) of section 351.

“(5) CONFIDENTIAL AND TRADE SECRET INFORMATION.—This subsection does not authorize the disclosure of any trade secret,

confidential commercial or financial information, or other matter described in section 552(b) of title 5.

“(b) CONTINUING EDUCATION.—The Secretary shall advance education and awareness among health care providers regarding biological products, including biosimilar biological products and interchangeable biosimilar biological products, as appropriate, including by developing or improving continuing education programs that advance the education of such providers on the prescribing of, and relevant clinical considerations with respect to, biological products, including biosimilar biological products and interchangeable biosimilar biological products.”.

The bill (S. 1681), as amended, was ordered to be engrossed for a third reading, was read the third time, and passed.

#### PROVIDING FOR STAFF TRANSITION FOR A SENATOR IF THE RESULTS OF THE ELECTION FOR AN ADDITIONAL TERM OF OFFICE OF THE SENATOR HAVE NOT BEEN CERTIFIED

Mr. BRAUN. Mr. President, I ask unanimous consent that the Senate proceed to the consideration of S. Res. 805, submitted earlier today.

The PRESIDING OFFICER. The clerk will report the resolution by title.

The senior assistant legislative clerk read as follows:

A resolution (S. Res. 805) providing for staff transition for a Senator if the results of the election for an additional term of office of the Senator have not been certified.

There being no objection, the Senate proceeded to consider the resolution.

Mr. BRAUN. I ask unanimous consent that the resolution be agreed to and that the motion to reconsider be considered made and laid upon the table with no intervening action or debate.

The PRESIDING OFFICER. Without objection, it is so ordered.

The resolution (S. Res. 805) was agreed to.

(The resolution is printed in today's RECORD under “Submitted Resolutions.”)

#### 1921 SILVER DOLLAR COIN ANNIVERSARY ACT

Mr. BRAUN. Mr. President, I ask unanimous consent that the committee on Banking, Housing, and Urban Affairs be discharged from further consideration of H.R. 6192 and the Senate proceed to its immediate consideration.

The PRESIDING OFFICER. Without objection, it is so ordered.

The clerk will report the bill by title.

The senior assistant legislative clerk read as follows:

A bill (H.R. 6192) to require the Secretary of the Treasury to honor the 100th anniversary of completion of coinage of the “Morgan Dollar” and the 100th anniversary of commencement of coinage of the “Peace Dollar”, and for other purposes.

There being no objection, the committee was discharged, and the Senate proceeded to consider the bill.

Mr. BRAUN. I ask unanimous consent that the bill be considered read a third time and passed and the motion to reconsider be considered made and laid upon the table.

The PRESIDING OFFICER. Without objection, it is so ordered.

The bill (H.R. 6192) was ordered to a third reading, was read the third time, and passed.

#### CIRCULATING COLLECTIBLE COIN REDESIGN ACT OF 2020

Mr. BRAUN. Mr. President, I ask unanimous consent that the committee on Banking, Housing, and Urban Affairs be discharged from further consideration of H.R. 1923 and that the Senate proceed to its immediate consideration.

The PRESIDING OFFICER. The clerk will report the bill by title.

The senior assistant legislative clerk read as follows:

A bill (H.R. 1923) to amend title 31, United States Code, to require the Secretary of the Treasury to mint and issue certain circulating collectible coins, and for other purposes.

There being no objection, the committee was discharged, and the Senate proceeded to consider the bill.

Mr. BRAUN. I ask unanimous consent that the Cortez Masto amendment, which is at the desk, be considered and agreed to; that the bill, as amended, be considered read a third time and passed; and that the motion to reconsider be considered made and laid upon the table.

The PRESIDING OFFICER. Without objection, it is so ordered.

The amendment (No. 2717) was agreed to, as follows

(Purpose: To improve the bill)

At the end, add the following:

#### SEC. 8. COST.

No coin or medal minted and issued under this Act, or an amendment made by this Act, may be sold at a price such that would result in a net cost to the Federal Government.

The amendment was ordered to be engrossed and the bill to be read a third time.

The bill was read the third time.

The bill (H.R. 1923), as amended, was passed.

#### THE CALENDAR

Mr. BRAUN. Mr. President, I ask unanimous consent that the applicable committees be discharged and the Senate proceed to the immediate consideration of the following bills en bloc: H.R. 3976, H.R. 5597, H.R. 7810, H.R. 5972, H.R. 4988, H.R. 5123, H.R. 5451, H.R. 5983, H.R. 6418, H.R. 7088, H.R. 7502, H.R. 8611, H.R. 6161, S. 4971, and S. 4857.

There being no objection, the committees, where applicable, were discharged, and the Senate proceeded to consider the bills en bloc.

Mr. BRAUN. I ask unanimous consent that the bills, en bloc, be considered read a third time and passed and that the motions to reconsider be considered made and laid upon the table, all en bloc.